Organic Active Ingredients TRIZ Cases

A lipid particle delivery carrier introduces therapeutic RNA into myeloid tumor cells using ionizable lipids with optimized pKa values.

Locked nucleotide antisense oligonucleotides block EZH2 binding to B2 RNA, maintaining cell viability under environmental stress.

[1,6]Naphthyridine compounds inhibit CDK8 and CDK19 to reduce STAT1 phosphorylation, resolving unspecific cytotoxic effects from poor selectivity.

Printed capillary channels in a barrier layer modulate drug release rates from a reservoir, preventing uneven distribution that alters lens optical clarity.

4-Azaindazole compounds antagonize Wnt signaling by blocking beta-catenin stabilization, correcting aberrant growth states in cancer treatment.

Polymorphic funapide forms improve chemical stability and bioavailability while managing formulation processing complexity.

Specific piperidine compounds deplete NAD levels in tumor cells to trigger apoptosis while sparing normal cellular energy metabolism.

Boronate ester crosslinked glycosaminoglycan hydrogels enable self-healing networks through reversible alkoxyboronate anion linkages.

Cured polyethylene oxide matrix increases crush resistance to prevent physical manipulation while maintaining prolonged pain relief.

Cas9 protein and guide RNA inactivate the VEGF-A gene, reducing treatment frequency for chronic eye diseases.

Continuous epidural citrate infusion dissolves compressive bone at neutral pH, avoiding nerve injury risks from mechanical laminectomy.

pH-sensitive lipid nanoparticles release irinotecan and microRNA in acidic tumors, reducing drug resistance and side effects.

A topical pharmaceutical composition combines bimatoprost and minoxidil to stimulate hair growth.

5-Acyl-6,7-dihydrothieno[3,2-c]pyridines inhibit Hedgehog acyltransferase to block Sonic hedgehog palmitoylation.

Branched-chain amino acids mitigate steroid-induced muscle wasting by suppressing atrophy genes without compromising anti-inflammatory efficacy.

Colloidal silicon dioxide enhances Voriconazole solubility, resolving low water solubility issues while maintaining manufacturing simplicity.

The AIR-CIS algorithm classifies breast cancer patients using gene expression modules to predict sensitivity to cyclin-dependent kinase inhibitors.

Disrupting TRAC and B2M genes enables immediate allogeneic CAR-T therapy, eliminating autologous manufacturing delays.

Bifunctional PROTACs overcome inhibitor limitations by recruiting E3 ligases to degrade TBK1 via the proteasome pathway.

EGFR pathway inhibitors administered with subunit vaccines enhance memory cell formation and reduce viral loads.

A Rhodiola rosea nanoemulsion uses specific surfactants and oils to create stable oil-in-water droplets.

A programmed Nitisinone dosing scheme creates chronic liver injury in FAH gene-deficient rats.

A guide RNA directs CRISPR/Cas9 to modify the ZNF274 binding site on chromosome 15, reducing protein interaction and reactivating silenced maternal transcripts.

Alkyl substituted azetidines resolve delivery efficiency and tissue specificity trade-offs by enabling efficient gene silencing in specific tissues.

Ionic gelation of sodium alginate with calcium salts creates enteric microcapsules containing diclofenac.

Segmented heterocyclic structures modulate lysophosphatidic acid receptors to treat fibrosis and cancer.

SNALP carriers protect siRNA from degradation while enabling targeted liver delivery to reduce triglyceride levels.

Bead formulations merge immediate-release antagonists and delayed agonists to reduce dry mouth side effects while maintaining therapeutic efficacy.

A quinazoline derivative forms a Michael addition reaction with cysteine residues on the EGFR receptor.

Small molecule macrocycles replace antibodies to block the PD-1 pathway, improving stability and bioavailability while reducing toxicity.

A synthesis process for fluticasone propionate uses soluble mixed fluorides and radical inhibitors to achieve selective fluorination.

2-Aryl oxazole compounds inhibit TRPM8 channels, reducing pain and itch symptoms while minimizing side effects in urological disorder treatments.

Bufalin derivatives modify chemical structures to increase solubility, addressing poor bioavailability in cancer treatment.

Liposomes deliver pre-polyglutamated pralatrexate to bypass cellular enzyme variability and overcome efflux pump resistance in tumors.

MEK1/2 inhibitors overcome hypoxic maturation blocks in pre-oligodendrocytes to treat white matter injury.

Topical RORC inhibitors block keratinocyte transformation to prevent skin cancer in high-risk patients.

Phosphatidylcholine stabilizes unstable nitric oxide for transdermal use, resolving the trade-off between gas stability and anti-inflammatory efficacy.

Topical lopinavir and ritonavir compositions inhibit skin cancer progression, reducing systemic side effects compared to invasive surgical procedures.

Antibodies bind HER3 epitopes to stabilize inactive states, blocking ligand-dependent and independent signaling pathways.

Selective HDAC8 inhibitors bind the catalytic site, resolving dose-limiting toxicities from non-selective inhibition.

A rotigotine adhesive layer combines alicyclic saturated hydrocarbon resin with specific aliphatic alcohols to enhance drug permeation.

Novel substituted oxindole derivatives resolve metabolic stability and CYP450 inhibition trade-offs while maintaining high V1b receptor selectivity.

Substituted pyrazolo piperidine carboxylic acids activate soluble guanylate cyclase to produce vasorelaxation.

Optimized pyrimidine compounds resolve pharmacokinetic constraints to treat respiratory syncytial virus infections.

Composite lipid nanoparticles protect nucleic acids from nuclease digestion while facilitating cellular uptake.